Related Experiment Videos
Kawasaki Disease: Current Therapeutic Perspectives.
Erik C. Michelfelder1, David Shim
1Division of Cardiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, C4, Cincinnati, OH 45229, USA. miche0@chmcc.org
Current Treatment Options in Cardiovascular Medicine
|July 3, 2002
Summary
Kawasaki disease, a childhood vasculitis, can cause heart issues. Standard treatment with intravenous gamma globulin and aspirin significantly reduces coronary artery problems, but management for some patients remains debated.
Area of Science:
- Pediatrics
- Cardiology
- Rheumatology
Background:
- Kawasaki disease is a leading cause of acquired heart disease in children.
- It involves acute systemic vasculitis, primarily affecting coronary arteries.
- Coronary artery abnormalities, including aneurysms and thrombosis, pose significant risks.
Purpose of the Study:
- To review the current standard treatment for Kawasaki disease.
- To discuss challenges and controversies in managing specific patient groups.
- To explore emerging therapeutic strategies for Kawasaki disease.
Main Methods:
- Review of current literature on Kawasaki disease treatment.
- Analysis of standard therapy protocols (intravenous gamma globulin and aspirin).
- Discussion of treatment for refractory cases and coronary artery aneurysms.
Main Results:
- Standard treatment (IVIG and high-dose aspirin) within 10 days reduces coronary abnormalities from 20-25% to ~5%.
- Management of persistent fever or coronary aneurysms remains controversial.
- Corticosteroids and newer antiplatelet agents show promise for specific patient groups.
Conclusions:
- Current standard therapy is effective but not universally successful.
- Further research is needed for optimal management of complex Kawasaki disease cases.
- Emerging therapies offer potential improvements in outcomes for affected children.